SIS 401 PACA
Alternative Names: SIS-401-PACALatest Information Update: 19 Oct 2023
At a glance
- Originator SiSaf
- Class Antineoplastics; MicroRNAs
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Pancreatic cancer
Most Recent Events
- 10 Oct 2023 Early research in Pancreatic cancer in United Kingdom (Parenteral), prior to October 2023 (SiSaf pipeline, October 2023)